A groundbreaking new drug for the treatment of type 1 diabetes has been administered to a teenage patient in the UK, marking a significant milestone in the fight against the chronic disease. Teplizumab, the new medication, works by reprogramming the immune system to prevent it from attacking the pancreatic cells responsible for insulin production, thereby delaying the onset of diabetes.
14-year-old Sam, from Kings Norton, underwent treatment with Teplizumab at Birmingham Children’s Hospital after screening revealed his predisposition to developing type 1 diabetes. His mother, Louise, expressed relief that Sam can now focus on his studies without the constant worry about his blood sugar levels, a luxury not afforded to those living with diabetes.
The decision to have Sam screened was influenced by the fact that his father, Chris, lives with type 1 diabetes, increasing the likelihood of his children inheriting the condition. Louise highlighted the challenges faced by individuals with diabetes, such as the need for constant monitoring of blood sugar levels and carrying insulin at all times, emphasizing the positive impact that Teplizumab has had on Sam’s quality of life.
According to Diabetes UK, over 400,000 individuals in the UK have type 1 diabetes, a condition for which there is no cure currently available. Unlike type 2 diabetes, which is more prevalent, type 1 diabetes requires insulin-dependent management. Birmingham Children’s Hospital has announced that Teplizumab will be prescribed on a case-by-case basis for children recently diagnosed with type 1 diabetes, offering hope for an extended period of normalcy in their lives. Dr. Renuka Dias, a diabetes consultant at the hospital, praised the potential of Teplizumab in providing children with a normal childhood for a longer duration, underscoring the importance of early intervention in the management of the disease
Read the full article from The BBC here: Read More
